Technology & Devices

Tavotek Enters Research Agreement with Genmab for Development of Bispecific Antibodies Using Genmab’s DuoBody Platform Against a Pair of Disease Relevant Targets

AMBLER, Pa., May 25, 2020 /PRNewswire/ — Tavotek Biotherapeutics, a biotech company which develops novel biologics for autoimmune diseases and oncology, announced that it has entered into a research agreement with Genmab A/S of Denmark to create and develop bispecific antibodies using Genmab’s DuoBody® technology platform against disease relevant target …

Read More »

Roche Acquires Stratos Genomics to Further Develop DNA Based Sequencing for Diagnostic Use

Basel, 22 May 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has acquired Stratos Genomics, an early-stage sequencing technology company to advance the development of Roche’s nanopore sequencer. The acquisition provides Roche access to Stratos Genomics unique chemistry, Sequencing by Expansion (SBX™). The Roche nanopore sequencer, …

Read More »

ArcherDX Receives FDA Breakthrough Device Designation for its NGS Device Under Development as a CDx to Detect NTRK Gene Fusions

BOULDER, Colo., May 19, 2020 /PRNewswire/ — ArcherDX, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its next-generation sequencing (NGS) device under development as a companion diagnostic (CDx) to detect neurotrophic receptor tyrosine kinase (NTRK) gene fusions that lead to the …

Read More »

Roche Enters Drug Discovery Collaboration with Vividion Focused on Novel E3 Ligases

SAN DIEGO, May 19, 2020 /PRNewswire/ — Vividion Therapeutics, a biotechnology company discovering and developing highly selective small molecule medicines that drug traditionally inaccessible targets, today announced that it has entered into an exclusive worldwide option and license agreement with Roche (SIX: RO, ROG;OTCQX: RHHBY) to leverage its proteomics screening …

Read More »

FDA Informs Public About Possible Accuracy Concerns with Abbott ID NOW Point-of-Care Test to Diagnose COVID-19

Today, the U.S. Food and Drug Administration is alerting the public to early data that suggest potential inaccurate results from using the Abbott ID NOW point-of-care test to diagnose COVID-19. Specifically, the test may return false negative results. “We are still evaluating the information about inaccurate results and are in …

Read More »

Bayer and ArcherDX Announce Global Collaboration to Develop NGS-based Companion Diagnostic for Vitrakvi

BOULDER, Colo. & BERLIN–(BUSINESS WIRE)–Bayer and ArcherDX, Inc. today announced a global collaboration for the development and commercialization of a next-generation sequencing (NGS)-based companion diagnostic (CDx) for Vitrakvi® (larotrectinib). The primary objective of the collaboration is to broaden patient access to comprehensive genomic testing inclusive of neurotrophic receptor tyrosine kinase 1 …

Read More »

Abbott Receives FDA Emergency Use Authorization for COVID-19 Molecular Test on New Alinity m System

ABBOTT PARK, Ill., May 12, 2020 /PRNewswire/ — Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the company’s molecular test for the novel coronavirus (COVID-19) for use on its new Alinity™ m molecular laboratory instrument. Abbott is in …

Read More »

Skyhawk and Merck Expand Collaboration Agreement with to Discover and Develop Novel Small Molecules that Modulate RNA Splicing

WALTHAM, Mass., May 12, 2020 /PRNewswire/ — Skyhawk Therapeutics, Inc. (“Skyhawk”) today announced that it has expanded its strategic collaboration with Merck, known as MSD outside the United States and Canada, to discover, develop and commercialize small molecules that modulate RNA splicing. Skyhawk’s proprietary SkySTARTM technology platform will be employed …

Read More »

Specifica Transfers Antibody Discovery Platform to Bayer

SANTA FE, N.M., May 12, 2020 /PRNewswire/ — Specifica, a leading provider of antibody discovery technologies, today announced the transfer of a suite of Specifica’s Generation 3 antibody libraries to Bayer under an agreement that will enable the development of antibody-based therapeutics. Antibody Libraries are the sources from which therapeutic …

Read More »

Novartis and Dyno Therapeutics Enter Ocular Collaboration to Develop Improved Gene Therapies with AAV Vectors based on AI Technology

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dyno Therapeutics, a biotechnology company applying artificial intelligence (AI) to gene therapy, today announced a collaboration with Novartis to develop improved Adeno-Associated Virus (AAV) vectors for research, development, and commercialization of gene therapies for ocular diseases. The partnership will allow the parties to utilize Dyno’s CapsidMap™ artificial intelligence …

Read More »